Beyond diabetes management: A narrative review on the neurological and psychiatric impact of semaglutide

Abstract: Semaglutide, a glucagon-like peptide-1 receptor agonist, has attracted increasing scientific interest for its potential relevance to neurological and psychiatric conditions beyond its established indications for type 2 diabetes and obesity. Emerging evidence from preclinical models, observational human studies, and early-phase clinical investigations suggests that semaglutide engages central nervous system pathways implicated in neurodegeneration, reward processing, and behavioral regulation. Proposed mechanisms include modulation of neuroinflammatory signaling, oxidative stress, protein aggregation, autophagy, mitochondrial function, and dopaminergic neurotransmission. This narrative review synthesizes current evidence examining semaglutide’s associations with neurological and psychiatric outcomes, including Alzheimer’s disease, Parkinson’s disease, substance use disorders, and disordered eating behaviors. Large-scale epidemiological studies report consistent associations between semaglutide exposure and reduced incidence or recurrence of several substance use and eating disorders, while preclinical models demonstrate biologically plausible effects on disease-relevant pathways. However, available human data are predominantly observational, and randomized controlled trials establishing clinical efficacy for off-label neuropsychiatric indications are limited or ongoing. Evidence regarding mood and anxiety outcomes is mixed, with randomized trial data in selected populations suggesting psychiatric safety comparable to placebo, contrasted by signals of potential risk in real-world and pharmacovigilance datasets. These findings highlight the importance of careful patient selection, monitoring, and further investigation. Ongoing clinical trials and mechanistic studies will be critical to clarifying semaglutide’s central effects, defining appropriate clinical contexts, and determining whether observed associations translate into meaningful therapeutic benefit.

Authors

Institutions

Publication Details

Journal
Brain Circulation
Published
2026-04-27
DOI
https://doi.org/10.4103/bc.bc_210_25
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond diabetes management: A narrative review on the neurological and psychiatric impact of semaglutide

Yuchuan Ding, Alexander Weiss
Brain Circulation
Diabetes Treatment and Management
article

Beyond diabetes management: A narrative review on the neurological and psychiatric impact of semaglutide

Yuchuan Ding, Alexander Weiss
article en

Abstract

Abstract: Semaglutide, a glucagon-like peptide-1 receptor agonist, has attracted increasing scientific interest for its potential relevance to neurological and psychiatric conditions beyond its established indications for type 2 diabetes and obesity. Emerging evidence from preclinical models, observational human studies, and early-phase clinical investigations suggests that semaglutide engages central nervous system pathways implicated in neurodegeneration, reward processing, and behavioral regulation. Proposed mechanisms include modulation of neuroinflammatory signaling, oxidative stress, protein aggregation, autophagy, mitochondrial function, and dopaminergic neurotransmission. This narrative review synthesizes current evidence examining semaglutide’s associations with neurological and psychiatric outcomes, including Alzheimer’s disease, Parkinson’s disease, substance use disorders, and disordered eating behaviors. Large-scale epidemiological studies report consistent associations between semaglutide exposure and reduced incidence or recurrence of several substance use and eating disorders, while preclinical models demonstrate biologically plausible effects on disease-relevant pathways. However, available human data are predominantly observational, and randomized controlled trials establishing clinical efficacy for off-label neuropsychiatric indications are limited or ongoing. Evidence regarding mood and anxiety outcomes is mixed, with randomized trial data in selected populations suggesting psychiatric safety comparable to placebo, contrasted by signals of potential risk in real-world and pharmacovigilance datasets. These findings highlight the importance of careful patient selection, monitoring, and further investigation. Ongoing clinical trials and mechanistic studies will be critical to clarifying semaglutide’s central effects, defining appropriate clinical contexts, and determining whether observed associations translate into meaningful therapeutic benefit.

Brain Circulation
Wayne State University (US)
Good health and well-being
Openalex Percentile: Top 6%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.